Alnylam Pharmaceuticals
ALNY
#660
Rank
S$48.83 B
Marketcap
S$365.80
Share price
-0.25%
Change (1 day)
-3.22%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): S$4.89

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$4.84. In 2025 the company made an earnings per share (EPS) of S$2.30.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.89112.41%
2025S$2.30
2023S-$4.51-62%
2022S-$11.8729.03%
2021S-$9.20-3.36%
2020S-$9.52-8.48%
2019S-$10.407.67%
2018S-$9.6639.74%
2017S-$6.9112.94%
2016S-$6.1238.84%
2015S-$4.41-32.88%
2014S-$6.57259.44%
2013S-$1.83-31.25%
2012S-$2.66

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$8.97 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$3.27-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$54.34 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$10.63-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.93-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.31-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$1.75-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$0.45-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA